
  
    
      
        Background_NNP
        Familial_NNP and_CC epidemiological_JJ studies_NNS have_VBP indicated_VBN that_IN
        there_EX is_VBZ a_DT strong_JJ genetic_JJ component_NN in_IN the_DT aetiology_NN of_IN
        diabetic_JJ nephropathy_NN in_IN Type_NNP I_PRP diabetes_NN patients_NNS [_NN 1_CD ,_, 2_CD ]_NN ._.
        Apolipoprotein_NNP E_NNP (_( apoE_NN )_) was_VBD discovered_VBN as_IN a_DT plasma_NN protein_NN
        involved_VBN in_IN the_DT metabolism_NN of_IN lipoproteins_NNS ._. Recently_RB ,_, the_DT
        apolipoprotein_NN E_NNP (_( 
        APOE_NNP )_) gene_NN has_VBZ been_VBN suggested_VBN to_TO be_VB
        a_DT risk_NN factor_NN for_IN the_DT development_NN of_IN micro-_NN and_CC
        macrovascular_NN complications_NNS in_IN diabetic_JJ patients_NNS ._.
        The_DT 
        APOE_NNP gene_NN is_VBZ polymorphic_JJ ._. There_EX are_VBP
        three_CD common_JJ alleles_NNS ,_, 
        E_NNP 2_CD ,_, E_NNP 3_CD ,_, and_CC 
        E_NNP 4_CD ,_, which_WDT code_NN for_IN three_CD major_JJ
        isoforms_NNS ,_, resulting_VBG in_IN six_CD common_JJ genotypes_NNS [_NN 3_CD ,_, 4_CD ]_NN ._.
        Individuals_NNS with_IN apoE_NN 2_CD have_VBP higher_JJR triglyceride_NN levels_NNS and_CC
        are_VBP associated_VBN with_IN lower_JJR cholesterol_NN compared_VBN to_TO
        individuals_NNS with_IN apoE_NN 3_CD ._. Individuals_NNS with_IN apoE_NN 4_CD often_RB have_VBP
        elevated_VBD plasma_NN cholesterol_NN levels_NNS ._. There_EX is_VBZ an_DT increased_VBN
        prevalence_NN of_IN cardiovascular_JJ disease_NN and_CC particularly_RB
        Alzheimer_NNP 's_POS disease_NN [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._.
        Apolipoprotein_NNP E_NNP polymorphism_NN may_MD influence_VB the_DT
        metabolism_NN of_IN lipoproteins_NNS in_IN diabetic_JJ patients_NNS ._. Several_JJ
        recent_JJ studies_NNS have_VBP suggested_VBN that_IN this_DT polymorphism_NN may_MD be_VB
        associated_VBN with_IN a_DT genetic_JJ predisposition_NN for_IN diabetic_JJ
        nephropathy_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Thus_RB ,_, 
        APOE_NNP is_VBZ an_DT important_JJ candidate_NN gene_NN
        for_IN the_DT development_NN of_IN microvascular_NN complications_NNS in_IN Type_NNP
        I_PRP diabetes_NN patients_NNS ._.
        The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO investigate_VB the_DT influence_NN
        of_IN 
        APOE_NNP gene_NN polymorphism_NN in_IN the_DT
        development_NN of_IN diabetic_JJ nephropathy_NN and_CC retinopathy_NN in_IN Type_NNP
        I_PRP diabetes_NN patients_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Patients_NNS
          In_IN this_DT study_NN ,_, all_DT patients_NNS were_VBD Russians_NNPS with_IN
          unrelated_JJ Type_NNP I_PRP diabetes_NN ._. All_DT diabetic_JJ patients_NNS for_IN the_DT
          case-control_JJ study_NN were_VBD recruited_VBN from_IN St_NNP ._. Petersburg_NNP
          Diabetological_NNP Centres_NNP and_CC had_VBD participated_VBN in_IN the_DT
          program_NN "_'' Diabetes_NNP mellitus_JJ "_'' (_( which_WDT included_VBD monitoring_NN of_IN
          trends_NNS and_CC examinations_NNS of_IN the_DT determinants_NNS of_IN vascular_NN
          complications_NNS in_IN Type_NNP I_PRP diabetes_NN )_) carried_VBD out_IN in_IN St_NNP ._.
          Petersburg_NNP ,_, Russia_NNP since_IN 1997_CD ._.
          The_DT diabetic_JJ patients_NNS included_VBN in_IN this_DT study_NN satisfied_VBD
          the_DT World_NNP Health_NNP Organization_NNP criteria_NNS for_IN diabetes_NN
          mellitus_JJ [_NN 12_CD ]_NN ._. Glycated_NNP haemoglobin_NN (_( HbAlc_NNP )_) was_VBD measured_VBN
          by_IN ion_NN exchange_NN chromatography_NN [_NN 13_CD ]_NN ._. At_IN entry_NN the_DT
          patients_NNS had_VBD HbAlc_NNP levels_NNS of_IN 5_CD ._. 7_CD to_TO 16_CD ._. 8_CD %_NN ._.
          The_DT Type_NNP I_PRP diabetes_NN groups_NNS consisted_VBD of_IN 74_CD subjects_NNS
          with_IN nephropathy_NN and_CC 92_CD subjects_NNS without_IN ._. The_DT study_NN
          covered_VBD 76_CD Type_NNP I_PRP diabetes_NN patients_NNS with_IN diabetic_JJ
          retinopathy_NN and_CC 96_CD patients_NNS without_IN ._. Some_DT subjects_NNS had_VBD
          more_JJR than_IN one_CD type_NN of_IN diabetic_JJ complication_NN ,_, and_CC
          consequently_RB were_VBD analysed_JJ in_IN more_JJR than_IN one_CD group_NN ._.
          For_IN Type_NNP I_PRP diabetes_NN patients_NNS ,_, all_PDT the_DT information_NN was_VBD
          examined_VBN for_IN evidence_NN of_IN nondiabetic_JJ renal_JJ disease_NN ._. Then_RB
          questionnaires_NNS ,_, medical_JJ records_NNS ,_, and_CC measurements_NNS of_IN
          albumin_NN excretion_NN were_VBD used_VBN to_TO determine_VB whether_IN they_PRP had_VBD
          diabetic_JJ nephropathy_NN ._. Those_DT patients_NNS were_VBD considered_VBN to_TO
          have_VB diabetic_JJ nephropathy_NN if_IN they_PRP were_VBD receiving_VBG
          treatment_NN for_IN renal_JJ disease_NN and_CC either_CC suffered_VBD from_IN
          persisting_VBG proteinuria_NN ,_, or_CC had_VBD persisting_VBG high_JJ
          albuminuria_NN ._. Urinary_NNP albumin_NN excretion_NN was_VBD measured_VBN by_IN
          nephelometry_NN [_NN 14_CD ]_NN ._. Nephropathy_NNP was_VBD defined_VBN as_IN a_DT
          persistent_JJ urinary_JJ albumin_NN excretion_NN of_IN more_JJR than_IN 20_CD
          μg_NN /_NN min_NN ,_, or_CC 30_CD mg_NN /_NN 24_CD h_NN in_IN two_CD out_IN of_IN three_CD consecutive_JJ
          urinalyses_NNS ._. Individuals_NNS with_IN no_DT history_NN of_IN nephropathy_NN
          and_CC no_DT albumin_NN excretion_NN were_VBD considered_VBN free_JJ of_IN
          nephropathy_NN ._.
          Fundus_NNP ophthalmoscopy_NN and_CC angiofluorography_NN were_VBD used_VBN
          to_TO diagnose_NN retinopathy_NN ._. The_DT diabetic_JJ retinopathy_NN group_NN
          consisted_VBD of_IN those_DT showing_VBG retinal_JJ change_NN ,_, while_IN Type_NNP I_PRP
          diabetes_NN control_NN group_NN were_VBD those_DT who_WP showed_VBD no_DT signs_NNS of_IN
          retinopathy_NN ._.
        
        
          DNA_NNP genotyping_VBG
          Blood_NNP was_VBD collected_VBN from_IN each_DT individual_JJ and_CC stored_VBD in_IN
          ethylenediaminetetraacetic_JJ acid_NN (_( EDTA_NNP )_) tubes_NNS at_IN -_: 20_CD °_NN C_NNP ._.
          Genomic_NNP DNA_NNP was_VBD obtained_VBN from_IN lysed_JJ white_JJ blood_NN cells_NNS by_IN
          phenol-chloroform_JJ extraction_NN ._. The_DT 
          APOE_NNP gene_NN polymorphism_NN was_VBD detected_VBN
          by_IN polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) ._. 
          APOE_NNP genotyping_VBG was_VBD performed_VBN by_IN
          the_DT method_NN of_IN Hixson_NNP and_CC Vernier_NNP [_NN 15_CD ]_NN using_VBG a_DT modified_VBN
          version_NN described_VBN by_IN Skobeleva_NNP et_CC al_NN ._. [_NN 16_CD ]_NN ._.
          The_DT sequence_NN of_IN the_DT sense_NN oligonucleotide_NN primer_NN was_VBD
          5_CD '_POS -_: AGATGCGGGCACGGCTGTTCAAGGA-_NNP 3_CD '_POS ,_, and_CC the_DT antisense_NN primer_NN
          was_VBD 5_CD '_POS -_: CCCTCGCGAGCCCCGGCCTGGTACAC-_NNP 3_CD '_POS [_NN 16_CD ]_NN ._. Each_DT
          amplification_NN reaction_NN contained_VBD 50_CD mM_NN KCl_NNP ,_, 10_CD mM_NN
          tris-_NN HCl_NNP pH_NN 8_CD ._. 4_CD ,_, 1_CD ._. 5_CD mM_NN MgCl_NNP 
          2_CD ,_, 0_CD ._. 25_CD μM_NN of_IN each_DT primer_NN ,_, 200_CD μM_NN
          dNTP_NN ,_, 10_CD %_NN DMSO_NNP ,_, 0_CD ._. 1_CD μg_NN DNA_NNP and_CC 1_CD U_NNP Tag_NNP polymerase_NN in_IN a_DT
          final_JJ volume_NN of_IN 20_CD μl_NN ._. After_IN denaturation_NN step_NN at_IN 95_CD °_NN C_NNP
          for_IN 5_CD minutes_NNS followed_VBN by_IN 30_CD cycle_NN of_IN denaturation_NN at_IN
          92_CD °_NN C_NNP (_( 1_CD min_NN )_) ,_, annealing_VBG at_IN 64_CD °_NN C_NNP (_( 1_CD min_NN )_) ,_, extension_NN at_IN
          72_CD °_NN C_NNP (_( 1_CD ._. 5_LS min_NN )_) and_CC a_DT final_JJ extension_NN at_IN 72_CD °_NN C_NNP (_( 5_CD min_NN )_)
          using_VBG a_DT MiniCycler_NNP (_( MJ_NNP Research_NNP ,_, Watertown_NNP ,_, MA_NNP ,_, USA_NNP )_) ._.
          Genotypes_NNP were_VBD determined_VBN by_IN 
          Hin_NNP 6_CD 1_CD (_( Fermentas_NNP ,_, Vilnius_NNP ,_,
          Lithuania_NNP )_) digestion_NN of_IN a_DT 244_CD -_: base_NN pair_NN PCR-amplified_NNP
          fragment_NN spanning_VBG the_DT two_CD polymorphic_JJ sites_NNS ._. The_DT digested_VBN
          DNA_NNP fragments_NNS were_VBD separated_JJ using_VBG migration_NN on_IN 12_CD %_NN
          polyacrylamide_NN gels_NNS and_CC visualized_JJ under_IN UV_NNP illumination_NN
          after_IN ethidium_NN bromide_NN staining_VBG [_NN 16_CD ]_NN ._. The_DT codominant_NN
          alleles_NNS 
          E_NNP 2_CD ,_, E_NNP 3_CD ,_, and_CC 
          E_NNP 4_CD determine_VB the_DT six_CD 
          APOE_NNP genotypes_NNS ._.
        
        
          Statistical_NNP testing_NN
          All_DT data_NNS are_VBP presented_VBN as_IN means_VBZ ±_NN SD_NNP ._. Groups_NNS were_VBD
          compared_VBN using_VBG the_DT Student_NNP 's_POS 
          t_NN test_NN for_IN comparison_NN of_IN two_CD groups_NNS
          for_IN quantitative_JJ variables_NNS ._. Allele_NNP frequency_NN among_IN
          control_NN subjects_NNS and_CC case_NN subjects_NNS were_VBD compared_VBN using_VBG
          standard_JJ Χ_NN 2_CD tests_NNS ._. The_DT difference_NN in_IN genotype_NN frequencies_NNS
          between_IN the_DT groups_NNS was_VBD tested_VBN by_IN Fisher_NNP 's_POS exact_JJ test_NN ._. A_DT
          value_NN of_IN P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN significant_JJ ._.
        
      
      
        Results_NNS
        Clinical_NNP characteristics_NNS by_IN study_NN group_NN are_VBP shown_VBN in_IN
        Table_NNP 1_CD ._. No_DT significant_JJ difference_NN was_VBD seen_VBN between_IN groups_NNS
        with_IN vascular_NN complications_NNS (_( nephropathy_NN and_CC retinopathy_NN )_)
        and_CC those_DT without_IN ,_, no_DT matter_NN the_DT age_NN ,_, diabetes_NN duration_NN ,_,
        age_NN at_IN diabetes_NN onset_NN ,_, and_CC mean_VB HbAlc_NNP ._.
        The_DT frequency_NN of_IN each_DT genotype_NN in_IN each_DT group_NN conformed_JJ
        to_TO the_DT Hardy_NNP -_: Weinberg_NNP equilibrium_NN ._.
        The_DT distribution_NN of_IN the_DT 
        APOE_NNP genotypes_NNS is_VBZ shown_VBN in_IN Table_NNP 2_CD ._.
        There_EX was_VBD no_DT significant_JJ difference_NN in_IN 
        APOE_NNP genotype_NN and_CC allele_NN frequency_NN
        between_IN nephropathic_JJ and_CC normoalbuminuric_JJ diabetic_JJ
        patients_NNS ._. In_IN this_DT study_NN ,_, no_DT association_NN was_VBD found_VBN between_IN
        diabetic_JJ retinopathy_NN and_CC 
        APOE_NNP polymorphisms_NNS ._. 
        APOE_NNP allele_NN frequencies_NNS for_IN males_NNS and_CC
        females_NNS were_VBD similar_JJ within_IN groups_NNS and_CC in_IN different_JJ
        groups_NNS ._.
      
      
        Discussion_NNP
        Diabetic_NNP nephropathy_NN and_CC diabetic_JJ retinopathy_NN are_VBP the_DT
        two_CD most_RBS important_JJ microangiopathic_JJ complications_NNS in_IN Type_NNP I_PRP
        diabetic_JJ patients_NNS ._. Many_JJ of_IN the_DT environmental_JJ factors_NNS that_WDT
        influence_NN the_DT risk_NN of_IN vascular_NN disease_NN are_VBP known_VBN ,_, but_CC
        genetic_JJ components_NNS of_IN the_DT risk_NN for_IN diabetic_JJ microangiopathy_NN
        are_VBP poorly_RB understood_VBN ._. Several_JJ candidate_NN genes_NNS have_VBP been_VBN
        investigated_VBN to_TO elucidate_NN the_DT genetic_JJ factors_NNS responsible_JJ
        for_IN vascular_NN complications_NNS ._. The_DT most_RBS important_JJ of_IN these_DT are_VBP
        the_DT aldose_NN reductase_NN gene_NN (_( 
        ALR_NNP 2_LS )_) [_NN 17_CD ]_NN ,_, the_DT insertion_NN /_NN deletion_NN
        (_( I_NN /_NN D_NNP )_) polymorphism_NN of_IN the_DT angiotensin_NN I_PRP -_: converting_VBG enzyme_NN
        (_( 
        ACE_NNP )_) gene_NN [_NN 18_CD ,_, 19_CD ]_NN ,_, C_NNP 825_CD T_NN
        polymorphism_NN of_IN the_DT gene_NN encoding_VBG the_DT beta-_NN 3_CD subunit_NN of_IN
        geterotrimeric_JJ G-_NNP proteins_NNS (_( 
        GNB_NNP 3_LS )_) [_NN 20_CD ,_, 21_CD ,_, 22_CD ]_NN ,_, and_CC C_NNP 677_CD T_NN
        polymorphism_NN of_IN the_DT methylenetetrahydrofolate_NN reductase_NN
        gene_NN (_( 
        MTHFR_NNP )_) [_NN 23_CD ]_NN ._.
        The_DT genetic_JJ polymorphism_NN of_IN apolipoprotein_NN E_NNP is_VBZ
        associated_VBN with_IN lipid_NN abnormalities_NNS ._. Eto_NNP et_CC al_NN ._. [_NN 9_CD ]_NN
        suggested_VBD that_IN lipid_NN abnormalities_NNS may_MD contribute_VB to_TO the_DT
        development_NN and_CC progression_NN of_IN kidney_NN disease_NN ,_, including_VBG
        diabetic_JJ nephropathy_NN ._. The_DT 
        E_NNP 2_CD allele_NN frequency_NN was_VBD significantly_RB
        higher_JJR in_IN Type_NNP II_NNP diabetes_NN patients_NNS with_IN nephropathy_NN (_( 7_CD ._. 2_LS %_NN )_)
        and_CC with_IN renal_JJ failure_NN (_( 9_CD ._. 7_CD %_NN )_) than_IN in_IN diabetic_JJ patients_NNS
        without_IN nephropathy_NN (_( 2_CD ._. 6_CD %_NN )_) [_NN 9_CD ]_NN ._. Apolipoprotein_NNP E_NNP
        polymorphism_NN is_VBZ associated_VBN with_IN the_DT progression_NN of_IN diabetic_JJ
        nephropathy_NN ._. Presence_NNP of_IN the_DT apolipoprotein_NN 
        E_NNP 4_CD allele_NN is_VBZ a_DT protective_JJ factor_NN ,_, and_CC
        other_JJ alleles_NNS entail_VB risk_NN factors_NNS [_NN 24_CD ]_NN ._.
        The_DT genes_NNS responsible_JJ for_IN genetic_JJ predisposition_NN to_TO
        vascular_NN complications_NNS are_VBP still_RB unknown_JJ ,_, and_CC little_JJ is_VBZ
        known_VBN about_IN the_DT molecular_JJ basis_NN of_IN these_DT complications_NNS ._. The_DT
        influence_NN of_IN the_DT 
        APOE_NNP gene_NN polymorphism_NN to_TO the_DT
        development_NN of_IN diabetic_JJ microangiopathy_NN is_VBZ uncertain_JJ ._.
        Chowdhury_NNP et_CC al_NN ._. [_NN 10_CD ]_NN and_CC Araki_NNP et_CC al_NN ._. [_NN 11_CD ]_NN demonstrated_VBD
        an_DT association_NN between_IN the_DT presence_NN of_IN the_DT 
        APOE_NNP E_NNP 2_CD allele_NN and_CC diabetic_JJ
        nephropathy_NN in_IN Caucasian_NNP patients_NNS with_IN Type_NNP I_PRP diabetes_NN ,_,
        although_IN some_DT investigators_NNS do_VBP not_RB support_VB this_DT association_NN
        [_NN 25_CD ,_, 26_CD ]_NN ._.
        This_DT study_NN elucidated_JJ the_DT role_NN of_IN 
        APOE_NNP gene_NN polymorphism_NN in_IN the_DT
        predisposition_NN to_TO diabetic_JJ vascular_NN complications_NNS ._. No_DT
        association_NN of_IN 
        APOE_NNP gene_NN polymorphism_NN with_IN diabetic_JJ
        nephropathy_NN was_VBD demonstrated_VBN ._. This_DT result_NN for_IN diabetic_JJ
        nephropathy_NN confirms_VBZ the_DT findings_NNS of_IN Tarnow_NNP et_CC al_NN ._. [_NN 25_CD ]_NN
        and_CC Onuma_NNP et_CC al_NN ._. [_NN 26_CD ]_NN ._. It_PRP should_MD be_VB mentioned_VBN that_IN sample_NN
        sizes_NNS in_IN [_NN 10_CD ,_, 11_CD ]_NN were_VBD larger_JJR than_IN in_IN this_DT study_NN ._. With_IN
        increased_VBN sample_NN size_NN comes_VBZ the_DT possibility_NN to_TO demonstrate_VB
        an_DT association_NN ._. But_CC the_DT larger_JJR the_DT necessary_JJ and_CC sufficient_JJ
        minimal_JJ sample_NN size_NN ,_, the_DT weaker_JJR the_DT association_NN
        demonstrated_VBN ._.
        We_PRP also_RB analysed_JJ the_DT association_NN of_IN the_DT 
        APOE_NNP gene_NN polymorphism_NN with_IN diabetic_JJ
        retinopathy_NN in_IN the_DT present_JJ study_NN ._. No_DT significant_JJ
        differences_NNS were_VBD found_VBN between_IN groups_NNS with_IN and_CC without_IN this_DT
        vascular_NN complication_NN ._. A_DT similar_JJ result_NN has_VBZ been_VBN shown_VBN by_IN
        Tarnow_NNP et_CC al_NN ._. [_NN 25_CD ]_NN for_IN diabetic_JJ retinopathy_NN ._.
      
      
        Conclusions_NNP
        The_DT present_JJ study_NN found_VBD no_DT evidence_NN for_IN a_DT role_NN of_IN the_DT 
        APOE_NNP gene_NN polymorphism_NN in_IN genetic_JJ
        susceptibility_NN for_IN the_DT development_NN of_IN diabetic_JJ retinopathy_NN
        in_IN Type_NNP I_PRP diabetes_NN patients_NNS ._. Association_NNP between_IN 
        APOE_NNP gene_NN polymorphism_NN and_CC diabetic_JJ
        nephropathy_NN may_MD be_VB weak_JJ or_CC moderate_JJ ,_, but_CC not_RB strong_JJ ._.
      
      
        COMPETING_NNP INTERESTS_NNP
        None_NN declared_VBD ._.
      
    
  
